In re Wellbutrin XL Antitrust Litigation
133 F. Supp. 3d 734
E.D. Pa.2015Background
- Plaintiffs (direct and indirect purchasers) allege GSK and Biovail delayed generic entry of Wellbutrin XL via settlement agreements with generic firms after Paragraph IV ANDAs and related patent litigation.
- The February 2007 “Wellbutrin Settlement” (multiple agreements) allowed continued patent litigation but guaranteed generic entry upon a finding of invalidity/noninfringement or by May 30, 2008; it included sublicenses to an independent Andrx patent, a Biovail supply guarantee, and a GSK promise not to launch an authorized generic during the 180‑day exclusivity period.
- Plaintiffs contend the no‑authorized‑generic term functioned as a reverse payment that delayed generic competition; GSK contends the settlement preserved litigation risk and produced procompetitive benefits (sublicense, supply, FTC review).
- District court previously dismissed sham‑litigation and citizen‑petition claims; remaining litigation focused on whether the settlement itself violated antitrust law under FTC v. Actavis and rule‑of‑reason analysis.
- The court evaluated (1) whether Actavis applies when the settlement leaves litigation pending, (2) whether plaintiffs proved anticompetitive effects, (3) procompetitive justifications, and (4) causation/antitrust injury; court granted GSK summary judgment.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Applicability of Actavis to settlement that preserves litigation | Settlement is a reverse payment (no‑AG) that should be analyzed under Actavis | Because settlement left patent litigation ongoing, it did not eliminate litigation risk and should escape Actavis scrutiny | Court: Actavis applies (rule‑of‑reason), but continuation of litigation is a relevant factor for the analysis; refused mechanical exemption |
| Anticompetitive effects under rule of reason | No‑AG promise was a valuable reverse payment that delayed generic entry | Settlement preserved risk of invalidity/non‑infringement and produced procompetitive outcomes; plaintiffs cannot show but‑for earlier entry | Court: Plaintiffs failed to show the Actavis‑type harm (induced abandonment) or a reliable but‑for alternative; no genuine dispute of material fact on anticompetitive effects |
| Procompetitive justifications (sublicense, supply, FTC review) | Justifications were pretextual; could have been achieved without no‑AG promise | Sublicense to Andrx patent and Biovail supply commitments were tangible, consumer‑benefiting terms unlikely attainable via litigation alone; enhanced FTC review was protective | Court: These justifications are procompetitive and a reasonable jury could not find harms outweighed benefits |
| Antitrust injury / causation (Clayton Act §4) | A large reverse transfer plus delay suffices to show injury and causation | Independent legal/regulatory barriers (valid patents, FDA approvals) break causation; plaintiffs must show generics would have entered but for the settlement and prevailed on patents | Court: Plaintiffs failed to prove causation/antitrust injury — Andrx patent independently barred entry and FDA regulatory timing limited any pre‑June 2007 launch; summary judgment for GSK |
Key Cases Cited
- FTC v. Actavis, Inc., 133 S.Ct. 2223 (U.S. 2013) (reverse‑payment settlements assessed under rule of reason; payments can sometimes violate antitrust law)
- King Drug Co. of Florence, Inc. v. SmithKline Beecham Corp., 791 F.3d 388 (3d Cir. 2015) (no‑authorized‑generic agreements can fall within Actavis and be treated as reverse transfers)
- United States v. Line Material Co., 333 U.S. 287 (U.S. 1948) (patent grants confer lawful exclusionary rights relevant to antitrust balance)
- United States v. Brown Univ., 5 F.3d 658 (3d Cir. 1993) (rule‑of‑reason burden allocation and procompetitive justification framework)
- Monsanto Co. v. Spray‑Rite Serv. Corp., 465 U.S. 752 (U.S. 1984) (conspiracy requires proof of conscious commitment to a common scheme to achieve an unlawful objective)
- Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574 (U.S. 1986) (limits on inferences from ambiguous circumstantial evidence of conspiracy)
- Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U.S. 100 (U.S. 1969) (patent rights implicate state power to exclude competitors; relevance to causation)
- City of Pittsburgh v. West Penn Power Co., 147 F.3d 256 (3d Cir. 1998) (independent regulatory schemes can sever antitrust causation)